Mindmed engages in productive pre-submission meeting with fda for development of the mindmed session monitoring system

New york, dec. 9, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies recently met with the united states food and drug administration (fda) center for devices and radiological health (cdrh) with consultation from the center for drug evaluation and research (cder) concerning several key points for ongoing development of the mindmed session monitoring system (msms) in a device pre-submission meeting that took place on october 25, 2021. mindmed presented fda with a working indications for use statement (ifu), and a development roadmap.
MNMD Ratings Summary
MNMD Quant Ranking